Barclays Maintains Overweight on CME Gr, Raises Price Target to $247
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Jeremy Campbell maintains an Overweight rating on CME Group (NASDAQ:CME) and raises the price target from $230 to $247.
October 10, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on CME Group and raises the price target from $230 to $247, which could lead to a positive market reaction.
The raised price target by Barclays indicates a positive outlook for CME Group. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100